[1]袁岳云,周冬斌,张向东.司库奇尤单抗治疗寻常性银屑病疗效及对患者皮损程度、炎性反应的影响[J].陕西医学杂志,2023,52(11):1578-1582.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.028]
　YUAN Yueyun,ZHOU Dongbin,ZHANG Xiangdong.Clinical efficacy of secukinumab in treating psoriasis vulgaris and its influence on skin lesion severity and inflammatory response in patients[J].,2023,52(11):1578-1582.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.028]
点击复制

司库奇尤单抗治疗寻常性银屑病疗效及对患者皮损程度、炎性反应的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年11期
页码:
1578-1582
栏目:
药物与临床
出版日期:
2023-11-05

文章信息/Info

Title:
Clinical efficacy of secukinumab in treating psoriasis vulgaris and its influence on skin lesion severity and inflammatory response in patients
作者:
袁岳云; 周冬斌; 张向东
(大同市第五人民医院,山西 大同 037009)
Author(s):
YUAN Yueyun; ZHOU Dongbin; ZHANG Xiangdong
(The Fifth People's Hospital of Datong,Datong 037009,China)
关键词:
司库奇尤单抗;  寻常性银屑病;  银屑病面积严重程度指数;  皮损面积;  皮肤病生活质量指数;  炎性反应
Keywords:
Secukinumab;  Psoriasis vulgaris;  Psoriasis Area Severity Index;  Skin lesion area;  Dermatology Life Quality Index;  Inflammatory reaction
分类号:
R 751.05
DOI:
DOI:10.3969/j.issn.1000-7377.2023.11.028
文献标志码:
A
摘要:
目的:探讨司库奇尤单抗治疗寻常性银屑病疗效及对患者皮损程度、炎性反应的影响。方法:选取96例寻常性银屑病患者,随机分为试验组(48例)和对照组(48例),对照组采用阿维A、复方甘草酸苷、卡泊三醇和卤米松软膏治疗,试验组采用司库奇尤单抗治疗。比较治疗前后两组患者病情严重程度[银屑病面积严重程度指数(PASI)、皮损面积(BSA)]、生活质量[皮肤病生活质量指数(DLQI)]及血清细胞因子[白细胞介素-17(IL-17)、白细胞介素-10(IL-10)、白细胞介素-22(IL-22)]的变化情况,观察司库奇尤单抗治疗寻常性银屑病患者的效果,并分析不良反应发生情况,随访患者复发率。结果:治疗12周后,试验组疗效优于对照组(P<0.05),两组患者的PSAI、BSA、DLQI评分、血清IL-17、IL-22水平均低于治疗前,且试验组显著低于对照组(均P<0.05)。两组患者的血清IL-10水平高于治疗前,且试验组显著高于对照组(P<0.05)。治疗结束后随访3个月期间,试验组复发率显著低于对照组(P<0.05)。结论:司库奇尤单抗治疗寻常性银屑病疗效确切,可缓解患者病情严重程度,有效抑制炎性反应,提高其生活质量,并有利于改善患者预后。
Abstract:
Objective:To explore the clinical efficacy of secukinumab in treating psoriasis vulgaris and its influence on skin lesion severity and inflammatory response in patients.Methods:96 patients with psoriasis were selected and randomly divided into test group(48 cases)and control group(48 cases).The control group was treated with acitretin,compound glycyrrhizin,calcipotriol and halometasone ointment,and the test group was given secukinumab.The disease severity(Psoriasis Area Severity Index [PASI],skin lesion area [BSA]),quality of life(Dermatological Life Quality Index [DLQI])and serum cytokines(interleukin-17 [IL-17],IL-10,IL-22)were compared between the two groups before and after treatment.The effect of secukinumab on patients with psoriasis vulgaris during treatment was observed,and the adverse reactions were analyzed and the recurrence rate of patients was followed up.Results:After 12 weeks of treatment,the efficacy in test group was better than that in control group(P<0.05); the PSAI score,BSA score,DLQI score and serum IL-17 and IL-22 levels in both groups were lower than those before treatment,and the scores and levels were significantly lower in test group than those in control group(all P<0.05); the level of serum IL-10 in the two groups was higher than that before treatment,and the level in test group was significantly higher than that in control group(all P<0.05).The recurrence rate in test group was significantly lower than that in control group during 3 months of follow-up after the end of treatment(P<0.05).Conclusion:Secukinumab has an exact efficacy in the treatment of psoriasis vulgaris,and it can alleviate the disease severity,effectively inhibit the inflammatory response,enhance the quality of life and help to improve the prognosis of patients.

参考文献/References:

[1] Blair HA.Secukinumab:A review in moderate to severe pediatric plaque psoriasis[J].Paediatric Drugs,2021,23(6):601-608.
[2] Elder JT,Bruce AT,Gudjonsson JE,et al.Molecular dissection of psoriasis:Integrating genetics and biology[J].J Invest Dermatol,2010,130(5):1213-1226.
[3] Lebwohl MG,Kavanaugh A,Armstrong AW,et al.US perspectives in the management of psoriasis and psoriatic arthritis:Patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis(MAPP)survey[J].Am J Clin Dermatol,2015,17(1):89-97.
[4] Rachakonda TD,Schupp CW,Armstrong AW.Psoriasis prevalence among adults in the United States[J].Journal of the American Academy of Dermatology,2014,70(3):512-516.
[5] Eisert L,Augustin M,Bach S,et al.S2k guidelines for the treatment of psoriasis in children and adolescents-short version part1[J].Journal der Deutschen Dermatologischen Gesellschaft,2019,17(8):856-870.
[6] 严松华,禚欣欣,顾丽娟,等.阿维A联合卡泊三醇软膏治疗斑块状银屑病的疗效及安全性分析[J].陕西医学杂志,2016,45(12):1673-1674.
[7] Nogueira M,Paller AS,Torres T.Targeted therapy for pediatric psoriasis[J].Paediatr Drugs,2021,23(3):203-212.
[8] 中华医学会皮肤性病学分会银屑病专业委员会.中国银屑病诊疗指南(2018完整版)[J].中华皮肤科杂志,2019,52(10):667-710.
[9] 曾碧君,蒋谷芬,周红霞,等.清热凉血粥对血热内蕴证银屑病角质细胞增殖与皮肤炎症干预作用[J].中国皮肤性病学杂志,2023,61(7):1-13.
[10] 袁 瑾,黄 悦,周昆丽,等.司库奇尤单抗治疗中重度斑块状银屑病疗效及安全性的真实世界研究[J].中国皮肤性病学杂志,2023,61(4):1-9.
[11] 郝运宏,李新新,翟鑫鼎,等.二联药物方案辅助窄谱中波紫外线治疗寻常型银屑病疗效研究[J].陕西医学杂志,2019,48(9):1212-1215.
[12] 张 丹,刘 青,盛亚玲,等.清热活血止痒汤联合窄谱中波紫外线治疗寻常型银屑病血热证疗效及对患者皮肤生理屏障功能的影响[J].陕西中医,2020,41(7):938-940.
[13] Cai L,Zhang JZ,Yao X,et al.Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis[J].Chin Med J(Engl),2020,133(22):2665-2673.
[14] Zhao Y,Cai L,Liu XY,et al.Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis:A real-life cohort study[J].Chin Med J(Engl),2021,134(11):1324-1328.
[15] Lee JE,Wang J,Florian J,et al.Effect of body weight on risk-benefit and dosing regimen recommendation of secukinumab for the treatment of moderate to severe plaque psoriasis[J].Clin Pharmacol Ther,2019,106(1):78-80.
[16] Schwensen JF,Clemmensen A,Sand C,et al.Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis:A retrospective multicenter study[J].Dermatol Ther,2017,30(2):12550.
[17] Rendon A,Schakel K.Psoriasis pathogenesis and treatment[J].Int J Mol Sci,2019,20(6):1475.
[18] 赵雨晴,魏志平,周 迪,等.舒肝健脾养血法对寻常型银屑病患者免疫功能、炎症因子的影响[J].陕西中医,2022,43(1):69-72.
[19] Mills KHG.IL-17 and IL-17-producing cells in protection versus pathology[J].Nat Rev Immunol,2023,23(1):38-54.
[20] Chiricozzi A,Romanelli P,Volpe E,et al.Scanning the immunopathogenesis of psoriasis[J].International Journal of Molecular Sciences,2018,19(1):179-210.
[21] Frieder J,Kivelevitch D,Menter A.Secukinumab:A review of the anti-IL-17A biologic for the treatment of psoriasis[J].Therapeutic Advances in Chronic Disease,2017,9(1):21-25.
[22] Hawkes JE,Chan TC,Krueger JG.Psoriasis pathogenesis and the development of novel targeted immune therapies[J].Journal of Allergy and Clinical Immunology,2017,140(3):645-653.
[23] Kim J,Krueger JG.Highly effective new treatments for psoriasis target the IL-23/Type17 T cell autoimmune axis[J].Annual Review of Medicine,2017,68(1):255-269.
[24] 王 静,江从军,陈 秋.银屑病患者血清IL-17、IL-22、IL-36与IL-36Ra水平的变化及其临床意义[J].中国美容医学,2019,28(8):77-79.
[25] 郑 易,潘丽娜,高 宇.白细胞介素10在银屑病中的表达特征及影响[J].温州医科大学学报,2023,53(1):7-14.
[26] 李玥熠,赵润生,郑书深.IL-22在银屑病发病机制中的研究进展[J].中国免疫学杂志,2021,37(9):1149-1152.
[27] 张 莉,陈利红,李 霞,等.IL-17A单克隆抗体治疗诱导期对寻常性银屑病患者血清细胞因子的影响[J].中国皮肤性病学杂志,2020,34(11):1249-1254.
[28] Hayashi M,Igarashi A,Okamura K,et al.Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris[J].Br J Dermatol,2019,180(3):684-685.

备注/Memo

备注/Memo:
基金项目:山西省卫生和计划生育委员会科研计划项目(ZDXM20220050)
更新日期/Last Update: 2023-11-06